title: [Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome. First six months of treatment].
abstract: OBJECTIVE
  The aim of this prospective study was to confirm the efficacy and safety of lansoprazole in patients with Zollinger-Ellison syndrome (ZES).
  
  
  METHODS
  Fourteen patients (5 W, 9 M) with ZES, age (mean +/- SD) 55.5 +/- 12.8 years, were included in the study.
  
  
  METHODS
  initially and at 1, 3 and 6 months thereafter the following items were assessed: clinical signs, fasting serum gastrin (FSG), basal acid output (BAO) before next dose of lansoprazole. BAO < 10 mmol H+/h was considered as efficient. Initially and at 6 months, laboratory tests (hematology, liver, renal and hormonal), endoscopy and histological enterochromaffin-like cell and gastrin cell density assessments were performed. Lansoprazole initial dose was adjusted according to clinical symptoms and secretory studies.
  
  
  RESULTS
  At 6 months, lansoprazole doses of 60, 90, 120 and 180 mg/d maintained BAO < 10 mmol H+/h in 9, 2, 1 and 1 patient, respectively. No significant changes in FSG, endocrine cells densities and biological parameters were noted during treatment. Neither adverse events nor carcinoid tumors were observed. We conclude that lansoprazole is efficient and well tolerated in patients with ZES.
authors.affiliation: Service d'Hépato-Gastroentérologie, Hôpital Bichat-Claude-Bernard, Paris.
authors.forename: D
authors.initials: D
authors.lastname: Pospaï
authors.forename: G
authors.initials: G
authors.lastname: Cadiot
authors.forename: S
authors.initials: S
authors.lastname: Forestier
authors.forename: P
authors.initials: P
authors.lastname: Ruszniewski
authors.forename: T
authors.initials: T
authors.lastname: Coste
authors.forename: J
authors.initials: J
authors.lastname: Escourrou
authors.forename: M
authors.initials: M
authors.lastname: Mignon
authors.lastname: Gresze
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D054328:Proton Pump Inhibitors; D012636:Secretory Rate / Q000187:drug effects; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D009853:Omeprazole
vernacular_title: Efficacité et tolérance du lansoprazole dans le traitement du syndrome de Zollinger-Ellison. Etude sur les six premiers mois de traitement.